Exelixis (NASDAQ:EXEL) has been upgraded from Neutral to Overweight in a statement by Piper Jaffray earlier today.
- Updated: October 10, 2016
Boasting a price of $12.95, Exelixis (NASDAQ:EXEL) traded 0.77% higher on the day. The last stock close price is up 58.47% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $12.62 and a two hundred day average of $8.24. Volume of trade was down over the average, with 3,286,105 shares of EXEL changing hands under the typical 6,190,070
Piper Jaffray has upgraded Exelixis (NASDAQ:EXEL) from Neutral to Overweight in a statement released on 10/10/2016.
On Thursday September 15, 2016, Stifel Nicolaus released a statement for Exelixis (NASDAQ:EXEL) bumped up the target price from $12.00 to $15.00 that suggested an upside of 0.15%.
With a total market value of $0, Exelixis has with a one year low of $3.55 and a one year high of $15.58 .
A total of 3 analysts have released a research note on EXEL. Three analysts rating the company a strong buy, 1 brokerage rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $7.00.
Brief Synopsis On Exelixis (NASDAQ:EXEL)
Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.